OBJECTIVE： To provide reference for reducing the occurrence of chemotherapy-induced constipation and optimizing constipation therapy. METHODS： Medical records of malignant lung tumor inpatients meeting inclusion criteria were collected from respiration department of our hospital， and then investigated and analyzed statistically in respects of patient’s gender， age， constipation history， tumor types and phases， physical status score， living habit change， chemotherapy plan （including adjuvant drug）， constipation occurrence， prevention and treatment， etc. The related factors of chemotherapy-induced constipation were investigated. RESULTS： A total of 135 patients were enrolled in the investigation. Of 135 patients， 66 patients had constipation with incidence of 48.89％， among which 96.97％ were grade 1 and grade 2 constipation. The onset of constipation were independent from age， gender and living habit change （P＞0.05）. The patients with history of constipation， advanced tumor stage， the period of treatment≥3 days， the use of palonosetron and combined with aprepitant had higher prevalence of constipation （P＜0.05）. The clinical symptoms were improved spontaneously in 21.21％ patients， 33.33％ after diet adjustment and 45.45％ by drug treatment as suppositories glycerol， lactulose； 24.24％ patients used lactulose to prevent constipation at rehospitalization. CONCLUSIONS： Chemotherapy-induced constipation was commonly occurred and related to serval factors and had not got enough attention yet. The clinical pharmacists should assist the physicians to make individual chemotherapy regimen as well as the prevention of adverse drug reactions.